I want to caution everyone a bit about the "lead" that we have on HU-211. If their "partner" is going to manufacture the product, then essentially no development work is going on with regards to manufacturing scale-up at the moment. There are often many pitfalls along the way to getting a scalable, reproducible, validatable, high quality product into the marketplace. The Phase III studies are not only important from a standpoint of product performance, but as, at least an initial test of the manufacturability of the product, and to provide the engineering group the time to properly develop the processes and validate the manufacturing line and process. If there are any significant hurdles, those have to be overcome, and Pharmos is somewhat at the mercy of the engineering group of whatever company with whom they partner.
I am not worried about the product being developed or being launched, (and probably launched first). I am not trying to "scare" anyone. I just want to point out that we are a bit away from Phase III implementation. I appreciate Pharmos being careful in choosing its partners, and I hope they choose one with good engineering capability and good manufacturing performance. But if one of the vertically integrated companies with a "competitive" product believes it can garner a big share of the market, that company can move with more money, more resources and internal coordination pretty quickly.
I believe in Pharmos' products and having been buying and holding long on Pharmos since before most people on this board, so please no flames about me being "short".
Good luck to all
Filbert |
